Ronald Hunt

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
New York, NY
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
By:/s/ Stephen Uden, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Ronald Hunt

Form 4 holding Director

Iterum Therapeutics plc

Security class
Ordinary Shares
Shares / value
253,898
Estimated value
$355,457
Report date
06 Aug 2024
Price
$1.40
Ownership
By New Leaf Ventures III, L.P.
Form 4 holding Director

Iterum Therapeutics plc

Security class
Ordinary Shares
Shares / value
91,122
Estimated value
$127,571
Report date
06 Aug 2024
Price
$1.40
Ownership
By New Leaf Biopharma Opportunities II, L.P.
Form 4 holding Director

Rallybio Corp

Security class
Option (Right to Buy)
Shares / value
14,305
Estimated value
$51,498
Report date
18 Feb 2026
Price
$3.60
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
Warrants (right to buy)
Shares / value
182,453
Estimated value
Report date
06 Aug 2024
Price
Ownership
By New Leaf Ventures III, L.P.
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
Warrants (right to buy)
Shares / value
65,481
Estimated value
Report date
06 Aug 2024
Price
Ownership
By New Leaf Biopharma Opportunities II, L.P.
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director, 10%+ Owner

Harpoon Therapeutics, Inc.

Security class
8.000% Series A Redeemable Preferred Stock
Shares / value
0
Estimated value
Report date
11 Mar 2024
Price
Ownership
Indirect
Form 4 holding Director, 10%+ Owner

Harpoon Therapeutics, Inc.

Security class
Common Stock Warrant (Right to Buy)
Shares / value
0
Estimated value
Report date
11 Mar 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Harpoon Therapeutics, Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
11 Mar 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
Subscription Rights (right to buy)
Shares / value
0
Estimated value
Report date
06 Aug 2024
Price
Ownership
By New Leaf Biopharma Opportunities II, L.P.
Underlying class
Units
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
Subscription Rights (right to buy)
Shares / value
0
Estimated value
Report date
06 Aug 2024
Price
Ownership
By New Leaf Ventures III, L.P.
Underlying class
Units
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
6.500% Exchangeable Senior Subordinated Note due 2025
Shares / value
$0
Estimated value
Report date
13 Jan 2025
Price
Ownership
By New Leaf Biopharma Opportunities II, L.P.
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Iterum Therapeutics plc

Security class
6.500% Exchangeable Senior Subordinated Note due 2025
Shares / value
$0
Estimated value
Report date
13 Jan 2025
Price
Ownership
By New Leaf Ventures III, L.P.
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Ronald Hunt

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .